RFS
FPRX

Rockefeller Financial Services’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Rockefeller Financial Services’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$141K Hold
6,444
– – ﹤0.01% 365
2017
Q3 		$264K Sell
6,444
-514
-7% -$16.1K 0.01% 309
2017
Q2 		$210K Buy
+6,958
New +$217K ﹤0.01% 292

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Rockefeller Financial Services's FPRX Position: Q4 2017 in Review

Rockefeller Financial Services held its Five Prime Therapeutics, Inc. (FPRX) position steady in Q4 2017 at 6,444 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #365.

Rockefeller Financial Services first reported a position in FPRX in Q2 2017 and has held it in 3 quarters since. The position peaked at $264K in Q3 2017. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

  • Rockefeller Financial Services held 6,444 shares of Five Prime Therapeutics, Inc. worth $141K as of Q4 2017.
  • Rockefeller Financial Services left its Five Prime Therapeutics, Inc. share count unchanged in Q4 2017.
  • Five Prime Therapeutics, Inc. made up ﹤0.01% of Rockefeller Financial Services's portfolio in Q4 2017, its #365 holding.
  • Rockefeller Financial Services first reported a position in Five Prime Therapeutics, Inc. in Q2 2017 and has held it in 3 quarters since.
  • Rockefeller Financial Services's Five Prime Therapeutics, Inc. position peaked at $264K in Q3 2017.
  • 137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on Rockefeller Financial Services's 13F filing for Q4 2017, filed 2 Feb 2018.